Cerenome (PSTV) Retained Earnings (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Retained Earnings of $535.3 million for Q1 2026, up 204.77% year-over-year from $175.6 million in Q1 2025, and up 203.76% quarter-over-quarter from -$515.9 million in Q4 2025.
Cerenome (PSTV) Retained Earnings (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Retained Earnings for 17 consecutive years, with $535.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 204.77% year-over-year to $535.3 million; the TTM figure through Mar 2026 stood at $535.3 million (up 204.77% YoY), while the FY2025 annual figure was -$515.9 million, down 4.54% from the prior year.
- Retained Earnings advanced to $535.3 million in Q1 2026 per PSTV's latest filing, from -$515.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at $535.3 million in Q1 2026 and bottomed at -$515.9 million in Q4 2025.
- Historically, Retained Earnings has averaged -$85.7 million across 5 years, with a median of -$461.5 million in 2022.
- Annual changes were most pronounced in 2025 — Retained Earnings slumped 206.56% — and 2026, when it soared 204.77%.
- Plus Therapeutics' Retained Earnings stood at $473.6 million in 2022, then increased by 1.19% to $479.3 million in 2023, then plunged by 202.96% to -$493.5 million in 2024, then retreated by 4.54% to -$515.9 million in 2025, then jumped by 203.76% to $535.3 million in 2026.
- Business Quant data shows PSTV's Retained Earnings at $535.3 million in Q1 2026, -$515.9 million in Q4 2025, and -$510.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 537.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 535.27 Mn |
| Dec 31, 2025 | -515.87 Mn |
| Sep 30, 2025 | -510.15 Mn |
| Jun 30, 2025 | 509.17 Mn |
| Mar 31, 2025 | -510.88 Mn |
| Dec 31, 2024 | -493.48 Mn |
| Sep 30, 2024 | -489.60 Mn |
| Jun 30, 2024 | -486.70 Mn |
| Mar 31, 2024 | 479.42 Mn |
| Dec 31, 2023 | 479.27 Mn |
| Sep 30, 2023 | -476.70 Mn |
| Jun 30, 2023 | -473.47 Mn |
| Mar 31, 2023 | 474.63 Mn |
| Dec 31, 2022 | 473.63 Mn |
| Sep 30, 2022 | -461.50 Mn |
| Jun 30, 2022 | -456.31 Mn |
| Mar 31, 2022 | 465.65 Mn |
| Dec 31, 2021 | 457.73 Mn |
| Sep 30, 2021 | 457.50 Mn |
| Jun 30, 2021 | 450.96 Mn |